RT Journal Article
SR Electronic
T1 Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
JF The Journal of Immunology
JO J. Immunol.
FD American Association of Immunologists
SP 6577
OP 6582
VO 151
IS 11
A1 Stancovski, I
A1 Schindler, D G
A1 Waks, T
A1 Yarden, Y
A1 Sela, M
A1 Eshhar, Z
YR 1993
UL http://www.jimmunol.org/content/151/11/6577.abstract
AB Cell surface molecules essential for the transformed phenotype or growth of malignant cells are attractive targets for anticancer immunotherapy. Antibodies specific to Neu/HER2, a human adenocarcinoma-associated growth factor receptor, were demonstrated to have tumor-inhibitory capacity. Yet, the inefficient accessibility of antibodies to solid tumors limits their clinical use. To redirect effector lymphocytes to adenocarcinomas, we constructed and functionally expressed in T cells chimeric single chain receptor genes incorporating both the Ag-binding domain of anti-Neu/HER2 antibodies and the zeta-signal-transducing subunit of the TCR/CD3 complex or the gamma-signal-transducing subunit of the Ig Fc receptor complex. Surface expression of the anti-Neu/HER2 chimeric genes in cytotoxic T cell hybridomas endowed them with specific Neu/HER2 recognition enabling their activation for IL-2 production and lysis of transformed cells overexpressing Neu/HER2. These chimeric genes hold promise for the immunotherapy of cancer.